Printed From BioPortfolio.com
FDA Grants Priority Review for AstraZeneca’s sBLA for Imfinzi in Advanced Non-Small Cell Lung Cancer
09:10 EDT 18 Oct 2017 | Speciality Pharma Journal
WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) for the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy. …
Original Article: FDA Grants Priority Review for AstraZeneca’s sBLA for Imfinzi in Advanced Non-Small Cell Lung Cancer
